Nephrology

An approval for sparsentan in focal segmental glomerulosclerosis would mark the second rare kidney disease approval for the agent.

Our top 5 headlines include a trial of gene-edited pig kidneys, a first-of-its-kind antibiotic approval, and new guidelines for migraine.

The genetically edited pig kidney was provided by eGenesis and successfully transplanted into a 66-year-old male patient with end-stage kidney disease.

Findings highlight the need for early frailty screening in dialysis patients and the implementation of appropriate interventions to improve outcomes.

Data from the phase 1 trial are intended to support dosing in a planned phase 2 trial in kidney transplant recipients.

Completion of the trial was announced in a financial update from Novo Nordisk, who explained the trial missed its primary endpoint for uACR improvement.

The month in review spotlights the top news and research in nephrology from January, including an FDA approval and new IgAN research.

Findings call attention to age-related neurodevelopmental differences between pediatric patients with CKD and healthy controls.

United Therapeutics’ investigational UKidney is derived from a 10 gene-edited source pig and will be tested in a clinical study of ESRD patients.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

In this episode, hosts discuss the approval of semaglutide (Ozempic) for reducing the progression of kidney disease in type 2 diabetes.

Garimella describes the overlap between diabetes and kidney disease, explaining the significance of semaglutide’s new indication for these patients.

Findings suggest the benefits of combined belatacept and tacrolimus immunosuppression after kidney transplantation for patient and all-cause graft survival.

The FDA approved semaglutide to reduce the risk of kidney disease worsening, kidney failure, and death due to CVD in those with T2D and CKD.

Patients who started dialysis as children but were not waitlisted until young adulthood faced worse outcomes than those who were listed before turning 18.

Results showed no difference in time to relapse, relapse rates, subsequent immunosuppression use, or kidney function between the medications.

Donor HCV positivity was not associated with acute rejection or recipient mortality 1-year post-renal transplant in HCV-negative recipients.

In this episode, hosts explore the latest updates to the ADA Standards of Care on therapeutic innovations and their real-world impact on diabetes management.

Findings highlight the wide variety of outcomes experienced by patients with IgAN and the limited insights offered by clinical data at diagnosis.

Study findings point to the prognostic value of anti-ETAR and anti-CXCR3 antibodies in IgA nephropathy and lupus nephritis.

Findings show differences in the clinicopathological characteristics and prognosis of patients with IgAN and nephrotic syndrome across renal pathologies.

The study leverages large US-based claims datasets and pathologist input to estimate the annual incidence and total prevalence of IgAN in the US.

ChatGPT effectively simplified information about more than 60 glomerular disease terms to enhance readability, but medical accuracy decreased.

US nephrologists estimate half of all FSGS patients are not optimally managed, according to Spherix Global Insights.

Findings from Spherix Global Insights show that practitioners consider nearly half of their C3G patients to be potential candidates for Fabhalta or Empaveli, if approved.